TITLE

Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

AUTHOR(S)
MacArthur, Rodger D.; Miller, Mark; Albertson, Timothy; Panacek, Edward; Johnson, David; Teoh, Leah; Barchuk, William
PUB. DATE
January 2004
SOURCE
Clinical Infectious Diseases;1/15/2004, Vol. 38 Issue 2, p284
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
As part of the Monoclonal Anti-TNF: A Randomized Controlled Sepsis (MONARCS) trial, which enrolled patients with suspected sepsis, we sought to determine whether adequate antibiotic therapy was associated with a decreased mortality rate. The study enrolled 2634 patients, 91% of whom received adequate antibiotic therapy. The mortality rate among patients given adequate antibiotic treatment was 33%, versus 43% among patients given inadequate treatment (P<.001). We conclude that adequate antibiotic therapy results in a significant decrease in the crude mortality rate among patients suspected of sepsis.
ACCESSION #
12082076

 

Related Articles

  • Contribution of genes polymorphism to susceptibility and outcome of sepsis. Tumangger, Harapan; Jamil, Kurnia F. // Egyptian Journal of Medical Human Genetics;2010, Vol. 11 Issue 2, p97 

    Sepsis and its sequelae are still a major cause of morbidity and mortality in intensive care units (ICU). The evidence that endogenous mediators actually mediate the individual's response to infection has led to various approaches to assess the individual's contribution to the course of the...

  • Widely varying TNF-α levels in patients with myasthenia gravis. Jin Soo Lee; In Soo Joo; Jung Im Seok // Neurological Sciences;Jun2009, Vol. 30 Issue 3, p259 

    Animal studies have indicated an important role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of myasthenia gravis (MG), and trials of monoclonal antibodies that block TNF-α have shown clinical improvement. However, before a TNF-α blocking agent is proposed for treatment of...

  • Anti-TNF-alpha mAbs associated with increased risk of herpes zoster.  // Formulary;Mar2009, Vol. 44 Issue 3, p91 

    The article focuses on a study which demonstrates anti-tumor necrosis factor (TNF)-alpha monoclonal antibodies (mAbs) associated with increased risk of herpes zoster in patients with rheumatoid arthritis (RA). Researchers assessed the risk of herpes in patients who switched treatments one time...

  • New hope for psoriatic arthritis. Guttman, Cheryl // Dermatology Times;Feb2008, Vol. 29 Issue 2, p38 

    The article presents a phase 3 study on golimumab (Centocor), a next-generation anti-tumor necrosis factor TNF-alpha monoclonal antibody, for the treatment of psoriatic arthritis. The study randomized patients to once-a-month subcutaneous injection with one of two doses of golimumab or placebo....

  • Influence of ustekinumab on body weight of patients with psoriasis: an initial report. Owczarczyk-Saczonek, Agnieszka; Placek, Waldemar; Rybak-d'Obyrn, Joanna; Wygonowska, Ewa // Advances in Dermatology & Allergology / Postepy Dermatologii i A;Feb2014, Vol. 31 Issue 1, p29 

    Introduction: Many recent epidemiological studies have shown the influence of treatment with anti-TNF-α on body mass of patients with psoriasis but there are no reports in the literature on the influence of ustekinumab on that parameter. Aim: To review the effect of ustekinumab therapy on...

  • A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Corstjens, Paul; Fidder, Herma; Wiesmeijer, Karien; Dood, Claudia; Rispens, Theo; Wolbink, Gert-Jan; Hommes, Daniel; Tanke, Hans // Analytical & Bioanalytical Chemistry;Sep2013, Vol. 405 Issue 23, p7367 

    Monitoring levels of biologicals against tumor necrosis factor (TNF) has been suggested to improve therapeutic outcomes in inflammatory bowel diseases (IBDs). This pilot study describes a rapid lateral flow (LF)-based assay for on-site monitoring of serum trough levels of humanized monoclonal...

  • Comment on: A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Savage, Eimear M.; Millar, Auleen M.; Taggart, Allister J. // Rheumatology;Jun2014, Vol. 53 Issue 6, p1154 

    A letter to the editor is presented in response to the article "A Case of Certolizumab-Induced Interstitial Lung Disease in a Patient with Rheumatoid Arthritis" by Ian Glaspole and colleagues in the December 2013 issue.

  • Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Miranda-Bautista, José; Gracia-Fernández, Celia; López-Ibáñez, María; Barrientos, María; Gallo-Moltó, Alejandra; González-Arias, Marina; González-Gil, Casilda; Díaz-Redondo, Alicia; Marín-Jiménez, Ignacio; Menchén, Luis // Digestive Diseases & Sciences;Jul2015, Vol. 60 Issue 7, p2130 

    Background: Previous studies analyzing lipid profile in small cohorts of patients with rheumatic and inflammatory bowel diseases (IBD) treated with TNFα blockers showed conflicting results. We aim to evaluate the effect of anti-TNFα monoclonal antibodies, infliximab and adalimumab, on...

  • Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Trarbach, T.; Moehler, M.; Heinemann, V.; Köhne, C.-H.; Przyborek, M.; Schulz, C.; Sneller, V.; Gallant, G.; Kanzler, S. // British Journal of Cancer;2/10/2010, Vol. 102 Issue 3, p506 

    Background:Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics